TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Alternative Treatments of Unexplained Chronic Fatigue

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 21 through 65.~2. Has severe debilitating fatigue that substantially reduces the quality of life.~3. Does not have any organic, psychological, or lifestyle problems that are the primary disorder and are likely to be the cause of this fatigue (see exclusionary criteria)~4. The severe, unexplained fatigue has persisted for at least six months.~5. Has not been previously treated by current physician for chronic fatigue.~6. Can speak and read English.~7. Is not pregnant or planning to become pregnant within six months.~8. Has a telephone.~Exclusion Criteria:~No known history of:~1. Bipolar disorder~2. Psychosis~3. Major Depressive Disorder~4. Sleep disorder~5. Anemia~6. Thyroid disease~7. Rheumatoid Arthritis~8. Systemic Lupus~9. Cancer~10. Heart disease~11. Liver disease

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Integrative Medicine (Type: None): Patients of MD practitioners trained in Complementary and Alternative Medicine
- Naturopath Doctors (Type: None): Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
- Chronic Fatigue Specialists (Type: None): Patients of MD's who specialize in treating Chronic Fatigue and related conditions
- Control Group (Type: None): Patients treated by primary care MDs in practice-based research networks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Contribution of Contrast Enhanced Ultrasound in the Diagnosis of Adnexal Torsion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman over 18 years old~* Woman affiliated to a social security~* Woman having received complete information on the organization of the research and having given her informed consent in written form.~* Planned surgical intervention for suspected adnexal torsion~Exclusion Criteria:~* Patients under a measure of legal protection,~* Contraindication to contrast injection Hypersensitivity to sulfur hexafluoride or any of the other ingredients, history of cardiac disease, respiratory distress syndrome, severe pulmonary hypertension..

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Case group (Type: EXPERIMENTAL): Diagnosis of adnexal torsion confirmed by the surgical intervention: woman allocated to case group
- Control group (Type: EXPERIMENTAL): Diagnosis of adnexal torsion not confirmed by the surgical intervention: woman allocated to control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repeat Antenatal Steroids Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Pregnant~* Gestational age \> 23.0 wks and \< 31.6 wks~* Singleton or twin pregnancy~* Intact membranes~* At-risk for spontaneous preterm delivery~* Received full course of corticosteroids within the previous 7 days~Exclusion criteria:~* Diagnosis of fetal lung maturity~* Chorioamnionitis~* Non-reassuring fetal testing~* Known major fetal anomaly~* Corticosteroid therapy, other than qualifying course~* Insulin dependent diabetes~* Active preterm labor at the time of randomization~* Delivery intended outside center~* Participation in any intervention study which influences neonatal morbidity or mortality~* Previous participation in this trial

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic lymphocytic leukemia (CLL), CLL/PLL (as defined by FAB), and PLL (B- and T-cell phenotypes) who have relapsed from or are refractory to at least one fludarabine-based regimen.~2. Absolute neutrophil count (ANC) \>= 1 x 10(9)/L and platelet count \>= 50 x 10(9)/L~3. Adequate liver function (total bilirubin \<= 1.5 x ULN, SGPT \<= 2.5 x ULN) and renal function (serum creatine \<= 1.5 x ULN).~4. ECOG performance status \<= 2.~Exclusion Criteria:~1. Patients with NYHA \>= grade 3 heart disease as assessed by history and/or physical examination~2. Pregnant or breastfeeding women or patients who are unwilling or unable to practice adequate contraception.~3. Chemotherapy within 4 weeks of starting therapy, or concurrent anticancer therapy (chemotherapy, radiotherapy, or biologic therapy)~4. Other malignancy within 3 years except in situ carcinoma~5. Unwilling or unable to provide informed consent~6. Hypersensitivity to nucleoside analogues~7. Other significant medical condition that compromises safety, compliance or study conduct, including but not limited to uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within 6 months, ventricular arrhythmia, diabetes, active infection, pulmonary fibrosis, and chronic hepatitis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Weekly Clofarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lexical Priming by Music in Alzheimer's Disease and Healthy Aging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for patients :~* Presence of diagnostic criteria for Alzheimer's disease~* Age ≥ 65 years~* MMSE (Mini-mental state Examination) ≥ 20~Exclusion Criteria for patient :~* Unstable clinical presentation or language presentation in the foreground~* Cognitive disorder of etiology different from that of Alzheimer's disease~Inclusion Criteria for volunteers :~* Age ≥ 18 years~* Absence of neurological or psychiatric antecedents~* For those aged 65 or over: MMSE (Mini-mental state Examination) greater than or equal to 27; non-pathological performance against the 5 words of Dubois and the verbal fluency test.~Exclusion Criteria for volunteers :~* Visual or auditory disorders insufficiently corrected~* Oral or written expression in French insufficient to carry out tests~* Consumption of psychotropic drugs not stabilized

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- patient with Alzheimer's Disease (Type: OTHER): 1. Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~2. Music Experience Questionnaire : questions about the past music training~3. Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.
- healthy volunteer (Type: OTHER): 1. Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~2. Music Experience Questionnaire : questions about the past music training~3. Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.~4. For volunteer over 65 years : Mini Mental State Examination, 5 words by Dubois and fluence verbal test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intestinal Permeability in Patients With Liver Cirrhosis Using Confocal Endoscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* liver cirrhosis~* need of upper endoscopy~* signed consent~* abdominal symptoms with indication for endoscopy~Exclusion Criteria:~* pregnancy~* Lactation~* Hypersensitivity to fluorescein~* Limited coagulation situation (Quick \<50%, PTT\> 50 sec, thrombocyte count \<50000 / μl or disturbed thrombocyte function) despite the substitution of coagulation factors / plasma products~* Limited or non-existent consent~* Restricted or inadequate ability to perform endoscopy and / or confocal imaging: restlessness of the patient, food residues, anatomical variants that make confocal imaging difficult (e.g., strictures)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liver cirrhosis (Type: None): Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
- Control group (Type: None): Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients admitted to the medical intensive care unit who require mechanical ventilation and are sedated with a GABA agonist with the expectation of being mechanically ventilated for greater than 24 hours.~Exclusion Criteria:~* Subjects who are less than 18 years~* Subjects who are pregnant (a pregnancy test will be performed on all women of child bearing age)~* Inability to obtain informed consent from the patient or his/her surrogate~* Subjects who are physiologically benzodiazepine dependent, and at risk of withdrawal syndromes~* Subjects with anoxic brain injuries, strokes, or neurotrauma~* Medical team following patient unwilling to change sedation regimen~* Subjects who are moribund and not expected to survive 24 hours or actively withdrawing medical support~* Documented allergy to study medications~* Subjects with advanced heart block at time of screening~* Prisoners~* RASS target of less than or equal to -4 at the time of screening~* PSG equipment unavailable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GABA agonist (Type: EXPERIMENTAL): None
- Alpha 2 agonist (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must have a histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic, unresectable, or recurrent.~2. Has received at most 1 line of prior non-gemcitabine chemotherapy for:~   * metastatic/unresectable disease.~  * Prior adjuvant gemcitabine, if completed more than 12 months prior to enrollment is not considered as prior line of therapy.~  * Radiosensitizing chemotherapy will not be considered a prior line of therapy.~3. Prior and concurrent therapy4. Measurable disease is required per RECIST criteria 1.1.~5. Age ≥18 years. 6. ECOG performance status 0 or 1 7. Anticipated life expectancy ≥ three months. 8. Central venous access 9. Availability of unstained slides or paraffin block tissue from archived tumor specimen. If not available the subject will undergo a fresh biopsy.~10. Specific pretreatment clinical laboratory parameters that are required within 14 days prior to registration.~11. Subjects must be recovered from any toxicity related to prior anti-neoplastic therapy (to grade \<1).~12. Women of child-bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.~Exclusion Criteria:~1. Receiving any other investigational agents.~2. Subjects with known untreated brain metastases.~3. Subjects receiving hepatic enzyme-inducing antiseizure drugs (EIASD~4. Uncontrolled intercurrent illness~5. Pregnancy~6. Any significant medical condition, laboratory abnormality, or psychiatric illness. 7. Any condition including the presence of laboratory abnormalities.~8. Any condition that confounds the ability to interpret data from the study. 9. Unwillingness or inability to comply with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARQ-761 (Type: EXPERIMENTAL): A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have provided written and signed informed consent;~2. Histologically confirmed invasive ductal carcinoma;~3. Planned to received (neo)/adjuvant chemotherapy;~4. Eastern Cooperative Oncology Group (ECOG) score of 0 to 1;~5. Can cope with HVLT-RDR and ADAS-Cog evaluation;~6. No prior therapy could induce neurological damage,within 4 weeks~7. Normal blood routine, liver and kidney functions within 1 week before enrollment in this study;~8. Women of childbearing age have a negative serum or urinary pregnancy tests prior to enrollment in this study; Pre-menopause women are contracepted with medically acceptable methods during the study period.~9. Compliance with the study protocol.~Exclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) score ≥ 2;~2. Hypersensitivity to experiment agents or components;~3. Women with pregnancy or breast feeding;~4. A clear past history of neurological or psychiatric disorders, including epilepsy or dementia;~5. Abnormal baseline impairment of cognitive impairment;~6. Poor compliance, unwillingness or inability to follow protocol to continue the study;~7. Any circumstances in which the investigator deemed the subject unsuitable for enrollment in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- experimental group (Type: EXPERIMENTAL): standard (neo)adjuvant chemotherapy plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
- Control group (Type: OTHER): standard (neo)adjuvant chemotherapy plus 250ml normal saline (NS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient requires below-knee bypass secondary to severe claudication, rest pain or tissue loss due to peripheral arterial occlusive disease.~2. Patient meets the disadvantaged autologous vein criteria described in Section 4.1.~3. Patient has a post-operative life expectancy greater than one year.~4. Patient is at least 21 years of age.~5. Patient is able to comply with all study requirements and be available for follow-up visits at 1, 6, 12, 24 and 36-months post-procedure.~6. Patient is willing and able to provide written, informed consent.~Exclusion Criteria:~1. Patient has had a previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or has known hypersensitivity to heparin.~2. Patient requires an infragenicular bypass for reasons other than peripheral arterial occlusive disease.~3. Patient requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts.~4. Patient is in need of, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure. However, inflow procedures that facilitate the bypass are permitted, as long as they are not performed at the same sitting as the bypass procedure.~5. Patient has been previously randomized for this study.~6. Patient has active infection in the region of graft placement.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GORE PROPATEN Vascular Graft: (Type: ACTIVE_COMPARATOR): None
- Disadvantaged Autologous Vein Graft (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed NODAT defined by pathologic OGTT (2h, 75mg glucose):~glucose ≥ 200mg/dl~* Defect in insulin secretion as judged by OGTT and HOMA B~* Renal transplantation (deceased or living donor) and treatment with the standard immunosuppression at our center, consisting of tacrolimus, mycophenolate mofetil, prednisone triple therapy without any induction~* stable graft function for more than 3 months post transplant~* informed consent of the patient~Exclusion Criteria:~* patients with prior history of type 1 or type 2 diabetes~* time since transplantation more than 20 years~* allergy against long-acting insulin or cyclosporine A~* body mass index (BMI) \> 35~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cyclosporine A (Type: EXPERIMENTAL): Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
- Tacrolimus (Type: ACTIVE_COMPARATOR): Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years~* High risk patients: General Surgery AKI Risk Index Class III, IV or V~* Major abdominal surgery~Exclusion Criteria:~* Ongoing acute kidney injury Stage 2/3~* History of kidney transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nephro Check Test (Type: EXPERIMENTAL): We take urine samples and analyse the level of \[TIMP-2\]●\[IGFBP-7\] using the NephroCheck Test to diagnose AKI
- serum creatinine measurement (Type: ACTIVE_COMPARATOR): This is the Golden standard to diagnose AKI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues